oxybutynin has been researched along with Hemorrhage, Uterine in 1 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaunitz, AM | 1 |
| Portman, D | 1 |
| Westhoff, CL | 1 |
| Archer, DF | 1 |
| Mishell, DR | 1 |
| Rubin, A | 1 |
| Foegh, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-label, Randomized, Parallel Group, Study of Efficacy and Safety of a Transdermal Contraceptive Delivery System (TCDS) in Comparison to a Low-dose Oral Contraceptive Containing 0.02 mg EE and 0.1 mg LNG in a 21-day Regimen.[NCT01181479] | Phase 3 | 1,504 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measuring the breakthrough bleeding (BTB) and/or breakthrough spotting (BTS). Measured as a percent of total number of cycles in each Arm/Group with BTB and/or BTS. (NCT01181479)
Timeframe: 6 months
| Intervention | percentage of cycles with BTB/BTS (Number) |
|---|---|
| AG200-15 for Cycle 1-6 | 23.9 |
| Lessina | 21.2 |
"Evaluation of patch adhesion was determined using the following scores:~0: >= 90% adhered (no lift)~>= 75% adhered but < 90% (some edges showing lift)~>= 50% adhered but < 75% (half of system lifts off)~< 50% (> half of system lifts off, but undetached)~patch completely detached" (NCT01181479)
Timeframe: 1 year
| Intervention | Score on a scale (Mean) |
|---|---|
| All Subjects Who Applied AG200-15 | 0.29 |
Pregnancy outcomes was determine by measuring Pearl index. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use. (NCT01181479)
Timeframe: AG200-15: 6 months; Lessina: 6 months; AG200-15: 1 year
| Intervention | Pearl Index (Number) |
|---|---|
| AG200-15 for Cycle 7-13 | 5.41 |
| Lessina | 6.67 |
| AG200-15 for Cycle 1-13 | 6.43 |
"Evaluation of irritation at application site was determined using the following scores:~0: None~Mild~Moderate~Severe" (NCT01181479)
Timeframe: 1 year
| Intervention | Score on scale (Mean) |
|---|---|
| All Subjects Who Applied AG200-15 | 1.35 |
"Evaluation of itching at patch application site was determined using the following scores:~0: None~Mild~Moderate~Severe" (NCT01181479)
Timeframe: 1 year
| Intervention | Score on a scale (Mean) |
|---|---|
| All Subjects Who Applied AG200-15 | 1.48 |
Measurement of plasma concentrations of LNG and EE for cycles 2, 6 and 13. (NCT01181479)
Timeframe: Lessina: 6 months; AG200-15: 1 year; AG200-15: 6 months
| Intervention | pg/ml (Mean) | |||||
|---|---|---|---|---|---|---|
| EE for cycle 2 | EE cycle 6 | EE cycle 13 | LNG cycle 2 | LNG cycle 6 | LNG cycle 13 | |
| AG200-15 for Cycle 1-13 | 30.5 | 36.7 | 31 | 1201 | 1753 | 1590 |
| AG200-15 for Cycles 7-13 | NA | NA | 33.4 | NA | NA | 1750 |
| Lessina Cycles 1-6 | 35.4 | 40.1 | NA | 2386 | 2611 | NA |
1 trial available for oxybutynin and Hemorrhage, Uterine
| Article | Year |
|---|---|
Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial.
Topics: Adolescent; Adult; Body Mass Index; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Dr | 2014 |